Brain Metastasis Clinical Trial
Official title:
IDO2 Genetic Status Informs the Neoadjuvant Efficacy of Chloroquine in Brain Metastasis Radiotherapy.
This research is being done to determine if a short course of Chloroquine (five weeks) before, during and after whole brain radiation therapy (WBRT) will improve the overall survival of subjects being treated for brain metastases.
Hypothesis one: A short course of chloroquine one week prior and four weeks after initiation
of WBRT is tolerable and significantly increases the median survival time of patients
suffering from brain metastasis as assessed one, three, six, nine, twelve and 24 months post
radiotherapy, when compared to historic controls.
Hypothesis two: The presence of one or both single-nucleotide polymorphisms (SNP)s in the
gene coding for the immunoregulatory enzyme indoleamine 2,3-dioxygenase 2 (IDO2) improves
the clinical outcomes of WBRT or the response to CQ co-treatment.
3.2. Specific Aims:
The specific aims of this study are:
1. Determine patients physical profiles prior WBRT and at regular intervals afterwards up
to 24 months after radiotherapy.
2. Record the status of patient metastases (i.e. number, location, size)
3. Determine patients' KPS values.
4. Record the incidence and causes of mortality of patients.
5. Determine the genotype of IDO2 for each patient.
6. Following data analysis, test the validity of the two hypotheses.
;
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT01913067 -
Evaluation of Cabazitaxel in Patients With Brain Metastasis Secondary to Breast Cancer and NSCLC
|
Phase 2 | |
| Completed |
NCT02662725 -
Ipilimumab Combined With a Stereotactic Radiosurgery in Melanoma Patients With Brain Metastases
|
Phase 2 | |
| Completed |
NCT00406835 -
Prospective Randomized Trial Between WBRT Plus SRS Versus SRS Alone for 1-4 Brain Metastases
|
Phase 3 | |
| Completed |
NCT01724801 -
Icotinib or Whole Brain Irradiation in EGFR-mutant Lung Cancer
|
Phase 3 | |
| Completed |
NCT00219297 -
Study of Patupilone in Patients With Brain Metastasis From Non-small Cell Lung Cancer
|
Phase 2 | |
| Withdrawn |
NCT02328300 -
FLT PET/MR for Evaluation of Pseudoprogression in Patients With Brain Lesions
|
||
| Terminated |
NCT01324635 -
Panobinostat and Stereotactic Radiation Therapy in Treating Patients With Brain Tumors
|
Phase 1 | |
| Terminated |
NCT01894633 -
Study of Whole-brain Irradiation With Chloroquine for Brain Metastases
|
Phase 2 | |
| Recruiting |
NCT02681549 -
Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer
|
Phase 2 | |
| Terminated |
NCT02279992 -
Pilot Study of Vardenafil and Carboplatin in Patients With Gliomas and Brain Metastases
|
Early Phase 1 | |
| Completed |
NCT02913534 -
Hypofractionated Stereotactic Radiation Therapy of Brain Metastases: Evaluation of Whole-brain Radiotherapy
|
N/A | |
| Completed |
NCT01942980 -
Evaluation of the Efficacy of Hippocampal Avoidance on the Cognitive Toxicity of Whole-Brain Radiation Therapy After Surgical Resection of Single Brain Metastasis of Breast Cancer
|
Phase 3 | |
| Terminated |
NCT01363557 -
Assess the Efficacy of Whole Brain Radiation Therapy in Lung Cancer Patients With Brain Metastasis
|
N/A | |
| Active, not recruiting |
NCT05102747 -
Stereotactic Radiotherapy in Oligometastatic Brain Disease: a Randomised Phase III Study Comparing Hypofractionated Stereotactic Radiation Therapy (3*10 Gy) to the Historical Single-dose Radiosurgery (1*20 to 25 Gy) With Medico-economic Evaluation.
|
N/A | |
| Recruiting |
NCT01891708 -
VEGFRs Predict Bevacizumab Benefit in Advanced Non Small Cell Lung Cancer
|
N/A | |
| Completed |
NCT01508221 -
Evaluation of the Use of Trental and Vitamin E For Prophylaxis of Radiation Necrosis
|
Phase 2 | |
| Completed |
NCT00587964 -
Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases
|
Phase 2 | |
| Not yet recruiting |
NCT06462079 -
Sacituzumab Govitecan Combined With Head Radiotherapy for Her2-negative Breast Cancer Brain Metastases
|
Phase 2 | |
| Not yet recruiting |
NCT02832635 -
A Clinical Trial on Whole-brain Radiotherapy With Temozolomide Concurrent Chemotherapy or Avoidance of Hippocampus for Patients of Brain Metastases
|
Phase 2 | |
| Completed |
NCT01395407 -
Phase I Trial of Stereotactic Radiosurgery Following Surgical Resection of Brain Metastases
|
Phase 1 |